Skip to main content
Triangle logo TriangleGet started

Decitabine (NCT04282187)

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms: a one-minute explainerNCT042821871 min

Decitabine trial for Acute Myeloid Leukemia (NCT04282187). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with a prior myeloproliferative neoplasm and at least 5% blasts in blood or marrow, who may qualify for a donor stem-cell transplant. Prior chemotherapy for this advanced disease excludes participation.

The idea: combine intravenous decitabine with one oral JAK inhibitor: ruxolitinib, fedratinib or pacritinib. Decitabine alters DNA methylation; JAK inhibitors block growth signals. Researchers measure how many patients reach transplant after up to six cycles.

This phase 2 study plans 25 patients. Anna Halpern leads it at Fred Hutch/University of Washington in Seattle, the single recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.